Modification of a lysine residue of adrenodoxin reductase, essential for complex formation with adrenodoxin.
The NADPH-cytochrome c reductase activity of NADPH-adrenodoxin reductase from NADPH to cytochrome c via adrenodoxin was inhibited by pyridoxal 5'-phosphate and other reagents that modified the lysine residues. However, the NADPH-ferricyanide reductase activity was not affected. Loss of the cytochrome c reductase activity could be prevented by adrenodoxin, but not by NADP+. One lysine residue of the adrenodoxin reductase could be protected from the modification with pyridoxal 5'-phosphate by complex formation with adrenodoxin. Loss of the NADPH-cytochrome c reductase activity was not due to the conformational change of the modified adrenodoxin reductase, judging from circular dichroism spectrometric studies.
D000302:Adrenal Cortex / Q000201:enzymology; D000325:Adrenodoxin / Q000378:metabolism*; D000818:Animals; D001665:Binding Sites; D002417:Cattle; D002942:Circular Dichroism; D005287:Ferredoxin-NADP Reductase / Q000378:metabolism*; D008239:Lysine / Q000031:analogs & derivatives / Q000378:metabolism*; D009245:NADH Dehydrogenase / Q000037:antagonists & inhibitors / Q000378:metabolism; D009247:NADH, NADPH Oxidoreductases / Q000378:metabolism*; D009249:NADP / Q000494:pharmacology; D009439:Neuraminidase / Q000378:metabolism; D011487:Protein Conformation; D011732:Pyridoxal Phosphate / Q000494:pharmacology; D013329:Structure-Activity Relationship
D000325:Adrenodoxin; D009249:NADP; D011732:Pyridoxal Phosphate; D005287:Ferredoxin-NADP Reductase; D009247:NADH, NADPH Oxidoreductases; D009245:NADH Dehydrogenase; D009439:Neuraminidase; D008239:Lysine